Neos Therapeutics (NEOS) PT Set at $20.00 by Cantor Fitzgerald

Neos Therapeutics (NASDAQ:NEOS) received a $20.00 price objective from research analysts at Cantor Fitzgerald in a research note issued to investors on Friday. The brokerage presently has a “buy” rating on the stock. Cantor Fitzgerald’s price objective suggests a potential upside of 125.99% from the company’s current price. Cantor Fitzgerald also issued estimates for Neos Therapeutics’ FY2018 earnings at ($1.86) EPS.

The analysts wrote, “Neos held its Analyst Day on March 22-23, which included a dinner with management and Behavioral Medicine KOLs Dr. Brian Barash and Dr. Birgit Amann, a presentation, and a manufacturing facility tour.””

How to Become a New Pot Stock Millionaire

NEOS has been the topic of several other reports. BidaskClub upgraded Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, March 10th. Zacks Investment Research lowered Neos Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, January 25th. Wells Fargo set a $14.00 price target on Neos Therapeutics and gave the company a “buy” rating in a research note on Saturday, March 17th. Finally, BMO Capital Markets lowered Neos Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 31st. One analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $15.00.

Neos Therapeutics (NEOS) opened at $8.85 on Friday. Neos Therapeutics has a 12 month low of $6.30 and a 12 month high of $13.15. The company has a debt-to-equity ratio of 7.47, a quick ratio of 2.14 and a current ratio of 2.20. The stock has a market capitalization of $256.62, a PE ratio of -3.19 and a beta of -0.20.

Neos Therapeutics (NASDAQ:NEOS) last issued its quarterly earnings results on Thursday, March 15th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.61) by $0.12. Neos Therapeutics had a negative return on equity of 437.92% and a negative net margin of 264.80%. The firm had revenue of $7.79 million for the quarter, compared to analyst estimates of $9.30 million. equities analysts anticipate that Neos Therapeutics will post -1.53 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in NEOS. Cortina Asset Management LLC bought a new stake in shares of Neos Therapeutics in the 3rd quarter valued at approximately $5,312,000. Lyon Street Capital LLC grew its stake in shares of Neos Therapeutics by 247.5% in the 4th quarter. Lyon Street Capital LLC now owns 783,583 shares of the company’s stock valued at $7,993,000 after purchasing an additional 558,117 shares during the period. BlackRock Inc. grew its stake in shares of Neos Therapeutics by 30.7% in the 4th quarter. BlackRock Inc. now owns 1,861,347 shares of the company’s stock valued at $18,985,000 after purchasing an additional 436,667 shares during the period. Perceptive Advisors LLC bought a new stake in shares of Neos Therapeutics in the 4th quarter valued at approximately $3,060,000. Finally, Harvest Capital Strategies LLC bought a new stake in shares of Neos Therapeutics in the 4th quarter valued at approximately $2,237,000. Institutional investors own 49.33% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was originally published by Ticker Report and is the sole property of of Ticker Report. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3297991/neos-therapeutics-neos-pt-set-at-20-00-by-cantor-fitzgerald.html.

About Neos Therapeutics

Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).

Analyst Recommendations for Neos Therapeutics (NASDAQ:NEOS)

Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Jewett-Cameron Trading Co  Stake Held by Fort Nelson Partners, LP
Jewett-Cameron Trading Co Stake Held by Fort Nelson Partners, LP
Greenhill & Co.  and GAMCO Investors  Critical Review
Greenhill & Co. and GAMCO Investors Critical Review
STRAKS Tops 1-Day Volume of $24,012.00
STRAKS Tops 1-Day Volume of $24,012.00
KlondikeCoin  Achieves Market Capitalization of $0.00
KlondikeCoin Achieves Market Capitalization of $0.00
Roku  and Its Competitors Head to Head Survey
Roku and Its Competitors Head to Head Survey
Pentair  vs. Metso  Financial Analysis
Pentair vs. Metso Financial Analysis


© 2006-2018 Ticker Report. Google+.